Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Cetuximab in Advanced Solid Tumors
NCT01166035Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2010
- Primary completion
- Sep 2011
- Countries
- 1
- Sponsor
- Medical University of Innsbruck
- Modality
- Small Molecules
- Drugs
- lenalidomide
- Conditions
- solid tumorcolorectal cancer (CRC)squamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in solid tumor, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (HNSCC) and 1 more, sponsored by Medical University of Innsbruck. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Lenalidomide + Cetuximab
Dose escalation of Lenalidomide with fixed dose Cetuximab
03
Who it enrols
Adult patients with advanced solid tumors (CRC, SCCHN, NSCLC) who have progressed on standard therapy, with adequate organ function and no prior IMiD therapy.
04
Endpoints
Primary
Maximum Tolerated Dose
Beyond the preview
Go deeper on NCT01166035.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01166035.